New drug combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT01838434
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involved 106 participants and looked at safety and how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
idelalisib and lenalidomide
What this could lead to
If it works, this combination could offer a new treatment option for people with mantle cell lymphoma that has come back or stopped responding to other therapies.
What could go wrong
This is an early-phase trial, so the benefits are not proven. The drugs may cause side effects, and the combination might not work better than lenalidomide alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States